NCT06119789 (MATRIX-Rare) is a Phase 2 clinical trial of Imatinib in Rare Malignant Neoplasm, sponsored by Oslo University Hospital.

Who is sponsoring NCT06119789?

NCT06119789 is sponsored by Oslo University Hospital.

What drugs are being tested in NCT06119789?

Interventions in NCT06119789: Imatinib, Trametinib, Dabrafenib.

What condition does NCT06119789 study?

NCT06119789 studies Rare Malignant Neoplasm.

Is NCT06119789 still recruiting?

NCT06119789 is currently recruiting now. Last updated 26 March 2025.

Last reviewed 2025-03-26 · How we verify

NCT06119789: MATRIX-Rare

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Precision Cancer Therapy in Rare Cancers

Recruiting now Phase 2 Last updated 26 March 2025

What this trial tests

Phase 2 trial testing Imatinib in Rare Malignant Neoplasm in 96 participants. Currently enrolling.

Timeline

20 March 2025

Primary endpoint
30 November 2033

1 August 2036

Quick facts

Lead sponsor	Oslo University Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	96
Start date	20 March 2025
Primary completion	30 November 2033
Estimated completion	1 August 2036
Sites	1 location across Norway

Drugs / interventions tested

Imatinib — full drug profile →
Trametinib (trametinib) — full drug profile →
Dabrafenib (dabrafenib) — full drug profile →

Conditions studied

Rare Malignant Neoplasm — all drugs for Rare Malignant Neoplasm →

Sponsor

Oslo University Hospital

Who can join

Adults 16 to 99, any sex, with Rare Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Imatinib

Trials testing the same drug.

NCT07530367 — A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Pati · Phase 3 · not yet recruiting
NCT07493408 — Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of · Phase 2 · not yet recruiting
NCT06124157 — A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adole · Phase 2 · recruiting
NCT06962254 — Imatinib and Trametinib for KRAS-mutated Solid Tumor · Phase 1 · recruiting
NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting

Other recruiting trials for Rare Malignant Neoplasm

Currently open trials in the same condition.

NCT05217407 — Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia · recruiting
NCT06872853 — Evaluation of Rare and Complex Tumours of the Thoraco-Abdominal and Soft Tissue District · recruiting

Other Oslo University Hospital trials

Trials by the same sponsor.

NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06119789 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
Last refreshed: 26 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06119789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing